Health
CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma – Medical Xpress
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the…
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine. The findings represent the longest follow-up published data to date for CAR T cell therapies approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory…
-
General21 hours agoFootballers and movie stars: PM’s Shanghai tourism push
-
Business20 hours agoNvidia reaches the $4 trillion mark. Can it hit $5 trillion in 2025?
-
Business20 hours agoThis artificial intelligence (AI) and “Magnificent Seven” stock will be the next company to surpass a $3 trillion market cap by the end of 2025
-
General18 hours ago‘Hidden and radical’ power of First Nations women unlocked in big hART’s Punkaliyarra project